Objets | Détails | Catégories |
---|---|---|
Budget
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
|
Politique ou Programme
|
Environnement
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
|
Règlement
|
Santé
|
Clinical Trials environment in Canada: operational issues, investment, enrollment
|
Politique ou Programme
|
Santé
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
|
Politique ou Programme
|
Propriété intellectuelle
|
Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver - Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility".
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
|
Politique ou Programme
|
Santé
|
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
|
Politique ou Programme
|
Santé
|
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade, establishment of an approval framework for subsequent entry biologic products, provision of data exclusivity for innovative drug products, review and approval of new drug submissions and post market surveillance of drug products and/or data protection and the regulation and protection of biopharmaceutical products.
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
Health Canada/PMPRB proposed regulation changes to the Patented Medicines Regulations.
|
Règlement
|
Santé
|
House of Commons Standing Committee of Health's (HESA) as it relates to Pharmacare, vision health, rare disease and/or any other pertinent legislative proposal before the committee
|
Proposition législative, Projet de loi ou résolution
|
Sciences et technologies
|
House of Commons Standing Committee of Industry and Technology (INDU) as it relates to Artificial Intelligence and/or any other pertinent legislative proposal before the committee
|
Proposition législative, Projet de loi ou résolution
|
Recherche et développement
|
House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee
|
Proposition législative, Projet de loi ou résolution
|
Impôts et finances
|
Income Tax Act as it relates to biopharmaceutical industry.
|
Politique ou Programme
|
Santé
|
Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare.
|
Politique ou Programme
|
Santé
|
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy
|
Politique ou Programme
|
Impôts et finances
|
Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED).
|
Politique ou Programme
|
Santé
|
National Pharmacare (Bill C-64, An Act respecting pharmacare)
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathways for drugs for rare diseases and the government strategy.
|
Règlement
|
Santé
|
Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal
|
Règlement
|
Impôts et finances
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
|
Règlement
|
Propriété intellectuelle
|
Pharmaceutical intellectual property protection as it relates to international trade agreements
|
Politique ou Programme
|
Santé
|
Pharmaceutical policy and any negotiations of a Health Accord or agreement with the Provinces/Territories, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing.
|
Politique ou Programme
|
Santé
|
Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions
|
Politique ou Programme
|
Santé
|
Policies related to the importation of pharmaceuticals from Canada to the United States
|
Politique ou Programme
|
Santé
|
Policies related to the National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathway for drugs for rare diseases and the government strategy.
|
Politique ou Programme
|
Santé
|
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
|
Règlement
|
Développement économique
|
Standing Committee on Finance (FINA) as it relates to pre-budget consultations.
|
Proposition législative, Projet de loi ou résolution
|
Développement économique
|
Strategic Innovation Fund, as it relates to any initiative submitted or supported
|
Subvention, Contribution ou autre avantage financier
|
Recherche et développement
|
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy.
|
Politique ou Programme
|
Commerce international
|
The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States.
|
Règlement
|
Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.
BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Adresse :
7070 Mississauga Road
Mississauga, ON L5N 5M8
Canada
Numéro de téléphone :
905-542-5555
Poste
5765
Numéro de fax :
905-542-5507
Hoffmann-La Roche Limited ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement
Ceci est le nom de l'agent responsable tel qu'indiqué dans l'enregistrement le plus récent de l'entreprise ou de l'organisation.
Nom | De | à |
---|---|---|
Hoffmann-La Roche Limited | 2024-04-05 | actuel |
Hoffmann-La Roche Limited | 2008-08-13 | 2024-04-05 |
Nom de l'agent responsable | De (aaaa-mm-jj) | À (aaaa-mm-jj) |
---|---|---|
BRIGITTE NOLET | 2022-08-01 | Actuel |
RONNIE MILLER | 2001-01-18 | 2022-08-01 |
Les déclarants sont tenus de soumettre un rapport mensuel de communications pour chaque communication orale et organisée avec un titulaire de charge publique désignée. Le nom du plus haut dirigeant rémunéré (c.-à-d. le déclarant) figurera sur tous les rapports mensuels de communications des lobbyistes salariés, que cette personne ait participé ou non aux communications.
Note :Les rapports mensuels de communications sont dus le 15e jour de chaque mois pour les communications qui ont eu lieu le mois précédent.
Les résultats ci-dessous sont triés par la date de publication au Registre des lobbyistes en ordre chronologique décroissant.
Les déclarants sont tenus de soumettre un rapport mensuel de communications pour chaque communication orale et organisée avec un titulaire de charge publique désignée. Le nom du plus haut dirigeant rémunéré (c.-à-d. le déclarant) figurera sur tous les rapports mensuels de communications des lobbyistes salariés, que cette personne ait participé ou non aux communications.
Note :Les rapports mensuels de communications sont dus le 15e jour de chaque mois pour les communications qui ont eu lieu le mois précédent.
Les résultats ci-dessous sont triés par la date de publication au Registre des lobbyistes en ordre chronologique décroissant.
Poste | Période d'occupation | Date du dernier jour d'occupation de la charge publique désignée |
---|---|---|
Press Secretary
Minister's Office, Environment Canada |
août 1999 à mars 2002 | Pas une charge désignée |
Press Secretary
Minister's Office, Environment Canada |
mars 1999 à août 1999 | Pas une charge désignée |
Communications Advisor to the Press Secretary
Minister's Office, Human Resources Development Canada |
mai 1988 à mars 1999 | Pas une charge désignée |